GlassScriptPhysician profile
Thomas V Sargero
NPI 1033104468
$82,407.54
in general payments reported to CMS, 2019-2025
71 companies · $3,652 in 2025
The $3,652 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $3,417 · 2021: $5,672 · 2022: $37K · 2023: $12K · 2024: $3,511 · 2025: $3,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,772 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,195.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,772.00 |
| Education | $191.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $28,996.53 | 2021-2025 | |
| Lilly USA, LLC | $15,830.19 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $15,189.70 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $3,140.31 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $2,588.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $1,617.81 | 2021-2025 | Minimed 780g |
| Amgen INC. | $1,399.19 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $856.82 | 2019-2025 | Jardiance, Tradjenta |
| Astellas Pharma US INC | $830.75 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $736.23 | 2019-2025 | Vraylar, Ubrelvy |
| Corcept Therapeutics | $735.18 | 2019-2025 | Korlym |
| Amarin Pharma, INC. | $697.54 | 2019-2023 | |
| Pfizer INC. | $688.27 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $679.95 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $676.47 | 2019-2024 |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $599.68 | 2019-2025 | Verquvo, Belsomra, Gardasil |
| Insulet Corporation | $592.56 | 2019-2025 | Omnipod |
| Exact Sciences Corporation | $523.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $433.54 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $379.81 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Nestle Healthcare Nutrition INC. | $374.89 | 2021-2023 | |
| Allergan, INC. | $373.23 | 2019-2020 | |
| Radius Health, INC. | $231.87 | 2019-2025 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $228.57 | 2019-2025 | Austedo Xr, Austedo Xr |
| Jazz Pharmaceuticals INC. | $206.25 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $192.96 | 2023-2024 | Rexulti, Nuedexta |
| Aimmune Therapeutics, INC. | $192.68 | 2024-2025 | Zenpep |
| Recordati_rare_diseases_inc. | $170.11 | 2021-2025 | Isturisa |
| Valeritas, INC. | $159.12 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $158.70 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $156.20 | 2023-2025 | Gemtesa |
| Avanir Pharmaceuticals, INC. | $148.70 | 2019-2022 | |
| Daiichi Sankyo INC. | $145.34 | 2019-2022 | |
| Biogen, INC. | $138.62 | 2020-2022 | |
| Glaxosmithkline, LLC. | $132.95 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Kowa Pharmaceuticals America, INC. | $116.23 | 2019-2021 | |
| Mannkind Corporation | $109.69 | 2020-2023 | Afrezza |
| Tandem Diabetes Care, INC. | $109.57 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Takeda Pharmaceuticals U.S.A., INC. | $102.26 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $98.94 | 2019-2022 | |
| Dexcom, INC. | $94.59 | 2019-2024 | Dexcom G6 Transmitter |
| Eisai INC. | $93.99 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $88.36 | 2020-2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.92 | 2019-2023 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $83.96 | 2020-2021 | |
| Celgene Corporation | $82.55 | 2019 | |
| Alexion Pharmaceuticals, INC. | $80.14 | 2024 | Ultomiris, Strensiq |
| Corium, LLC | $77.71 | 2023 | Adlarity |
| Esperion Therapeutics, INC. | $77.40 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $69.57 | 2022 | |
| Grifols USA, LLC | $63.60 | 2024 | Prolastin-C Liquid |
| Paratek Pharmaceuticals, INC. | $62.06 | 2025 | Nuzyra, Xhance |
| Phathom Pharmaceuticals, INC. | $61.56 | 2024 | Voquezna |
| Lundbeck LLC | $60.63 | 2024-2025 | Rexulti |
| Ascensia Diabetes Care US INC. | $59.81 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $58.37 | 2022-2025 | Ingrezza |
| Evoke Pharma, INC. | $53.60 | 2022-2024 | |
| Cequr Corporation | $51.71 | 2024 | Cequr Simplicity |
| Axsome Therapeutics, INC. | $46.40 | 2022-2025 | Sunosi |
| Acadia Pharmaceuticals INC | $44.38 | 2019-2021 | |
| Abbott Laboratories | $43.92 | 2019-2020 | |
| Zealand Pharma US, INC. | $30.15 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $29.18 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $27.62 | 2024-2025 | |
| Philips North America LLC | $26.89 | 2022 | |
| Vifor Pharma, INC. | $26.11 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.78 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $20.72 | 2022 | |
| Vivus LLC | $19.29 | 2019 | |
| Pulmonx Corporation | $14.49 | 2024 | Zephyr Delivery Catheter, Chartis Catheter, Zephyr Endobronchial Valve |
| Grt US Holding, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sargero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.